These involve the dual actions of MT1 receptor-mediated down-regulation of dihydrotestosterone (DHT)-activated AR signaling, and inhibition of activated nuclear factor-kappa B (NF-κB) signaling in prostate cancer cells [20,21,22,23]. This evidence concerns the gene NFKB1 and prostate carcinoma.